JP2022058682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022058682A5 JP2022058682A5 JP2022007043A JP2022007043A JP2022058682A5 JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5 JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5
- Authority
- JP
- Japan
- Prior art keywords
- synergistic combination
- gram
- composition
- amino acid
- antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644944P | 2012-05-09 | 2012-05-09 | |
| US61/644,944 | 2012-05-09 | ||
| US201261737239P | 2012-12-14 | 2012-12-14 | |
| US61/737,239 | 2012-12-14 | ||
| JP2019221319A JP2020054370A (ja) | 2012-05-09 | 2019-12-06 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221319A Division JP2020054370A (ja) | 2012-05-09 | 2019-12-06 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022058682A JP2022058682A (ja) | 2022-04-12 |
| JP2022058682A5 true JP2022058682A5 (https=) | 2023-01-04 |
Family
ID=49551273
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511698A Expired - Fee Related JP6608697B2 (ja) | 2012-05-09 | 2013-05-09 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| JP2018086685A Withdrawn JP2018138045A (ja) | 2012-05-09 | 2018-04-27 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| JP2019221319A Pending JP2020054370A (ja) | 2012-05-09 | 2019-12-06 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| JP2022007043A Pending JP2022058682A (ja) | 2012-05-09 | 2022-01-20 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511698A Expired - Fee Related JP6608697B2 (ja) | 2012-05-09 | 2013-05-09 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| JP2018086685A Withdrawn JP2018138045A (ja) | 2012-05-09 | 2018-04-27 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| JP2019221319A Pending JP2020054370A (ja) | 2012-05-09 | 2019-12-06 | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10813983B2 (https=) |
| EP (2) | EP3685851A1 (https=) |
| JP (4) | JP6608697B2 (https=) |
| KR (3) | KR20210121313A (https=) |
| CN (1) | CN104736172A (https=) |
| AU (3) | AU2013259512B2 (https=) |
| BR (1) | BR112014027842A2 (https=) |
| CA (1) | CA2872902A1 (https=) |
| DK (1) | DK2849782T3 (https=) |
| ES (1) | ES2784136T3 (https=) |
| HK (1) | HK1211484A1 (https=) |
| IL (3) | IL235527B2 (https=) |
| IN (1) | IN2014MN02437A (https=) |
| MX (2) | MX389127B (https=) |
| RU (2) | RU2018121290A (https=) |
| WO (1) | WO2013170015A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210121313A (ko) | 2012-05-09 | 2021-10-07 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| KR20200023521A (ko) | 2012-05-09 | 2020-03-04 | 콘트라펙트 코포레이션 | 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 |
| AU2015279705B2 (en) * | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| SG11201707345VA (en) * | 2015-03-12 | 2017-10-30 | Micreos Human Health Bv | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
| AU2016324307B2 (en) | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR20190004799A (ko) * | 2016-05-12 | 2019-01-14 | 콘트라펙트 코포레이션 | 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법 |
| CA3067542A1 (en) | 2017-06-19 | 2018-12-27 | Syddansk Universitet | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections |
| CA3069679A1 (en) * | 2017-07-10 | 2019-01-17 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
| KR20200124724A (ko) * | 2018-02-26 | 2020-11-03 | 콘트라펙트 코포레이션 | 변형된 PlySs2 리신 및 이의 용도 |
| CN112867398A (zh) * | 2018-06-22 | 2021-05-28 | 康特拉费克特公司 | 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感 |
| CN109668873B (zh) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | 一种活载体疫苗活性检测装置及其使用方法 |
| AU2020218748B2 (en) * | 2019-02-05 | 2023-12-21 | Biomedit, Llc | A genetically modified lactobacillus and uses thereof |
| CA3134154A1 (en) * | 2019-03-22 | 2020-10-01 | Contrafect Corporation | Method of treating infective endocarditis |
| EP3980049A4 (en) * | 2019-04-11 | 2023-07-19 | Contrafect Corporation | METHOD OF TREATMENT AND PREVENTION OF BONE AND JOINT INFECTIONS |
| WO2021127452A1 (en) * | 2019-12-19 | 2021-06-24 | Georgia State University Research Foundation, Inc. | Compounds for the treatment of bacterial infections and potentiation of antibiotics |
| WO2021236636A1 (en) * | 2020-05-19 | 2021-11-25 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| RU2755817C1 (ru) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ снижения грамположительной микрофлоры в кишечнике птицы |
| KR102528412B1 (ko) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
| WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
| CN115105491B (zh) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | 丝氨酸在制备抑制猪链球菌药物中的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8108587A (en) | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| CA2251724A1 (en) * | 1996-04-15 | 1997-10-23 | Paul Averback | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| EP1162994A4 (en) | 1999-02-25 | 2004-12-29 | New Horizons Diagnostics Inc | COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF STREPTOCOCCAL INFECTIONS |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| AU2003291614A1 (en) | 2002-05-17 | 2004-04-08 | New Horizons Diagnostics Corporation | Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| US7638600B2 (en) | 2004-03-24 | 2009-12-29 | The Rockefeller University | Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores |
| WO2008018854A2 (en) | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| CA2620903A1 (en) | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
| WO2009029192A1 (en) | 2007-08-24 | 2009-03-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
| EP3263588A1 (en) * | 2008-07-03 | 2018-01-03 | The Rockefeller University | Isolated staphylococcus-specific soluble binding molecule |
| KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| WO2011091412A1 (en) | 2010-01-25 | 2011-07-28 | Alere Scarborough, Inc. | A25 bacteriophage lysin |
| US20120271770A1 (en) * | 2011-04-20 | 2012-10-25 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
| EP2699689A4 (en) * | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| CA2833409A1 (en) | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| US9016640B2 (en) | 2011-04-22 | 2015-04-28 | Rks Design, Inc. | Instrument retention assembly |
| US20140120074A1 (en) | 2011-04-27 | 2014-05-01 | Lysando Ag | Antimicrobial agents |
| KR20210121313A (ko) | 2012-05-09 | 2021-10-07 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| KR20200023521A (ko) * | 2012-05-09 | 2020-03-04 | 콘트라펙트 코포레이션 | 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 |
-
2013
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/ko not_active Ceased
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/ru unknown
- 2013-05-09 MX MX2014013586A patent/MX389127B/es unknown
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/da active
- 2013-05-09 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en not_active Ceased
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 ES ES13787128T patent/ES2784136T3/es active Active
- 2013-05-09 HK HK15112347.8A patent/HK1211484A1/xx unknown
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/pt not_active IP Right Cessation
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/ru active
- 2013-05-09 US US14/399,575 patent/US10813983B2/en not_active Expired - Fee Related
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/ko not_active Withdrawn
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/ko not_active Expired - Fee Related
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/zh active Pending
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en not_active Ceased
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/ja not_active Expired - Fee Related
- 2013-06-04 US US13/909,618 patent/US9889181B2/en not_active Expired - Fee Related
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/es unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en not_active Ceased
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/ja not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/ja active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058682A5 (https=) | ||
| JP2022163214A5 (https=) | ||
| RU2020133461A (ru) | Предотвращение, разрушение и обработка биопленки лизином бактериофага | |
| Rivera et al. | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistantstaphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| Eckmann et al. | Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin | |
| Feld | Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons | |
| Plouffe | Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid | |
| Finney et al. | Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections | |
| JP2014518849A5 (https=) | ||
| RU2018107249A (ru) | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики | |
| HRP20131170T1 (hr) | Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija | |
| Paterson | Clinical experience with recently approved antibiotics | |
| Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
| Oksuz et al. | Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics | |
| Chaftari et al. | Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients | |
| JP2021513865A5 (https=) | ||
| CN101175531A (zh) | 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物 | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| Marie et al. | Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. | |
| Kajihara et al. | Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis | |
| Bell et al. | Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008) | |
| JP2022525914A5 (https=) | ||
| Suh | Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review of the literature | |
| Fiore et al. | The possible role of anti-methicillin-resistant Staphylococcus aureus antimicrobial agents in spontaneous bacterial peritonitis |